Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

An In Vivo Functional Screen Identifies JNK Signaling As a Modulator of Chemotherapeutic Response in Breast Cancer.

Ashenden M, van Weverwijk A, Murugaesu N, Fearns A, Campbell J, Gao Q, Iravani M, Isacke CM.

Mol Cancer Ther. 2017 Sep;16(9):1967-1978. doi: 10.1158/1535-7163.MCT-16-0731. Epub 2017 Jun 13.

2.

New insights for identification of doping with recombinant human erythropoietin micro-doses after high hydration.

Martin L, Ashenden M, Bejder J, Hoffmann M, Nordsborg N, Karstoft K, Morkeberg J, Sharpe K, Lasne F, Marchand A.

Drug Test Anal. 2016 Nov;8(11-12):1119-1130. doi: 10.1002/dta.2004. Epub 2016 Jul 8.

PMID:
27390252
3.

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine.

Lipinski KA, Barber LJ, Davies MN, Ashenden M, Sottoriva A, Gerlinger M.

Trends Cancer. 2016 Jan;2(1):49-63. doi: 10.1016/j.trecan.2015.11.003. Epub 2016 Jan 29. Review.

4.

Acute hyperhydration reduces athlete biological passport OFF-hr score.

Bejder J, Hoffmann MF, Ashenden M, Nordsborg NB, Karstoft K, Mørkeberg J.

Scand J Med Sci Sports. 2016 Mar;26(3):338-47. doi: 10.1111/sms.12438. Epub 2015 Mar 13.

PMID:
25773052
5.

Stability of athlete blood passport parameters during air freight.

Ashenden M, Sharpe K, Plowman J, Allbon G, Lobigs L, Baron A, Gore CJ.

Int J Lab Hematol. 2014 Oct;36(5):505-13. doi: 10.1111/ijlh.12178. Epub 2013 Dec 27.

PMID:
24373122
6.

Detection of microdoses of rhEPO with the MAIIA test.

Mørkeberg J, Sharpe K, Karstoft K, Ashenden MJ.

Scand J Med Sci Sports. 2014 Aug;24(4):634-41. doi: 10.1111/sms.12049. Epub 2013 Jan 24.

PMID:
23347069
7.

Improved alignment of reticulocyte counts between Sysmex XT-2000i instruments.

Ashenden M, Sharpe K, Habel J, Vicentin A, Schischka S.

J Clin Pathol. 2013 Mar;66(3):232-7. doi: 10.1136/jclinpath-2012-201151. Epub 2012 Oct 30.

PMID:
23112117
8.

Stability of athlete passport parameters during extended storage.

Ashenden M, Clarke A, Sharpe K, d'Onofrio G, Plowman J, Gore CJ.

Int J Lab Hematol. 2013 Apr;35(2):183-92. doi: 10.1111/ijlh.12014. Epub 2012 Oct 15.

PMID:
23067319
9.

Pericytes promote selective vessel regression to regulate vascular patterning.

Simonavicius N, Ashenden M, van Weverwijk A, Lax S, Huso DL, Buckley CD, Huijbers IJ, Yarwood H, Isacke CM.

Blood. 2012 Aug 16;120(7):1516-27. doi: 10.1182/blood-2011-01-332338. Epub 2012 Jun 27. Erratum in: Blood. 2012 Nov 15;120(20):4274. Huijber, Ivo J [corrected to Huijbers, Ivo J].

10.

Evaluation of the MAIIA dipstick test to detect recombinant human erythropoietin in plasma.

Ashenden M, Sharpe K, Garnham A, Gore CJ.

J Pharm Biomed Anal. 2012 Aug-Sep;67-68:123-8. doi: 10.1016/j.jpba.2012.04.025. Epub 2012 Apr 25.

PMID:
22578970
11.

Preanalytical mixing of whole-blood specimens in the context of the Athlete Passport.

Ashenden M, Clarke A, Sharpe K, d'Onofrio G, Allbon G, Gore CJ.

J Clin Pathol. 2012 Jan;65(1):8-13. doi: 10.1136/jclinpath-2011-200269. Epub 2011 Nov 2.

PMID:
22049219
12.

Quality control technique to reduce the variability of longitudinal measurement of hemoglobin mass.

Gough CE, Sharpe K, Ashenden MJ, Anson JM, Saunders PU, Garvican LA, Bonetti DL, Gore CJ, Prommer N.

Scand J Med Sci Sports. 2011 Dec;21(6):e365-71. doi: 10.1111/j.1600-0838.2011.01316.x. Epub 2011 Apr 28.

PMID:
21535184
13.

Net haemoglobin increase from reinfusion of refrigerated vs. frozen red blood cells after autologous blood transfusions.

Ashenden M, Mørkeberg J.

Vox Sang. 2011 Nov;101(4):320-6. doi: 10.1111/j.1423-0410.2011.01493.x. Epub 2011 Apr 28.

PMID:
21534982
14.

Current markers of the Athlete Blood Passport do not flag microdose EPO doping.

Ashenden M, Gough CE, Garnham A, Gore CJ, Sharpe K.

Eur J Appl Physiol. 2011 Sep;111(9):2307-14. doi: 10.1007/s00421-011-1867-6. Epub 2011 Feb 20.

PMID:
21336951
15.

Detecting autologous blood transfusions: a comparison of three passport approaches and four blood markers.

Mørkeberg J, Sharpe K, Belhage B, Damsgaard R, Schmidt W, Prommer N, Gore CJ, Ashenden MJ.

Scand J Med Sci Sports. 2011 Apr;21(2):235-43. doi: 10.1111/j.1600-0838.2009.01033.x.

PMID:
19903320
16.

Modification of gene expression: help to detect doping with erythropoiesis-stimulating agents.

Varlet-Marie E, Audran M, Ashenden M, Sicart MT, Piquemal D.

Am J Hematol. 2009 Nov;84(11):755-9. doi: 10.1002/ajh.21525. No abstract available.

17.

Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications.

Macdougall IC, Ashenden M.

Adv Chronic Kidney Dis. 2009 Mar;16(2):117-30. doi: 10.1053/j.ackd.2008.12.010. Review.

PMID:
19233071
18.

Screening for autologous blood transfusions.

Mørkeberg J, Belhage B, Ashenden M, Bornø A, Sharpe K, Dziegiel MH, Damsgaard R.

Int J Sports Med. 2009 Apr;30(4):285-92. doi: 10.1055/s-0028-1105938. Epub 2009 Feb 6.

PMID:
19199200
19.

Delta efficiency calculation in Tour de France champion is wrong.

Gore CJ, Ashenden MJ, Sharpe K, Martin DT.

J Appl Physiol (1985). 2008 Sep;105(3):1020; author reply 1021. doi: 10.1152/japplphysiol.90459.2008. No abstract available.

20.

Changes in red blood cell volume, plasma volume, and total blood volume after autologous blood collections.

Morkeberg J, Belhage B, Rasmussen AB, Damsgaard R, Ashenden MJ, Dziegiel MH.

Transfusion. 2008 Jul;48(7):1524-6. doi: 10.1111/j.1537-2995.2008.01768.x. No abstract available.

PMID:
18651913
21.

Effects of Hemopure on maximal oxygen uptake and endurance performance in healthy humans.

Ashenden MJ, Schumacher YO, Sharpe K, Varlet-Marie E, Audran M.

Int J Sports Med. 2007 May;28(5):381-5. Epub 2006 Oct 6.

PMID:
17024639
22.

The effects of microdose recombinant human erythropoietin regimens in athletes.

Ashenden M, Varlet-Marie E, Lasne F, Audran M.

Haematologica. 2006 Aug;91(8):1143-4. Epub 2006 Jul 25.

23.

A third generation approach to detect erythropoietin abuse in athletes.

Sharpe K, Ashenden MJ, Schumacher YO.

Haematologica. 2006 Mar;91(3):356-63. Epub 2006 Feb 17.

25.

Longitudinal variation of hemoglobin and reticulocytes in elite rowers.

Ashenden MJ, Lacoste A, Orhant E, Audran M, Sharpe K.

Haematologica. 2004 Nov;89(11):1403-4.

26.

Effect of pre-competition and altitude training on blood models used to detect erythropoietin abuse by athletes.

Ashenden MJ, Sharpe K, Schoch C, Schumacher YO.

Haematologica. 2004 Aug;89(8):1019-20.

27.

Contemporary issues in the fight against blood doping in sport.

Ashenden M.

Haematologica. 2004 Aug;89(8):901-3. No abstract available.

28.

Standardization of reticulocyte values in an antidoping context.

Ashenden MJ, Sharpe K, Damsgaard R, Jarvis L.

Am J Clin Pathol. 2004 Jun;121(6):816-25.

PMID:
15198353
29.

Doping with artificial oxygen carriers: an update.

Schumacher YO, Ashenden M.

Sports Med. 2004;34(3):141-50. Review.

PMID:
14987124
30.

Detection of hemoglobin-based oxygen carriers in human serum for doping analysis: confirmation by size-exclusion HPLC.

Varlet-Marie E, Ashenden M, Lasne F, Sicart MT, Marion B, de Ceaurriz J, Audran M.

Clin Chem. 2004 Apr;50(4):723-31. Epub 2004 Feb 5.

31.

Detection of hemoglobin-based oxygen carriers in human serum for doping analysis: screening by electrophoresis.

Lasne F, Crepin N, Ashenden M, Audran M, de Ceaurriz J.

Clin Chem. 2004 Feb;50(2):410-5. Epub 2003 Nov 21.

32.

Proof of homologous blood transfusion through quantification of blood group antigens.

Nelson M, Popp H, Sharpe K, Ashenden M.

Haematologica. 2003 Nov;88(11):1284-95.

33.

Effect of altitude on second-generation blood tests to detect erythropoietin abuse by athletes.

Ashenden MJ, Gore CJ, Parisotto R, Sharpe K, Hopkins WG, Hahn AG.

Haematologica. 2003 Sep;88(9):1053-62.

34.

The effect of common hematologic abnormalities on the ability of blood models to detect erythropoietin abuse by athletes.

Parisotto R, Ashenden MJ, Gore CJ, Sharpe K, Hopkins W, Hahn AG.

Haematologica. 2003 Aug;88(8):931-40.

35.

Second-generation blood tests to detect erythropoietin abuse by athletes.

Gore CJ, Parisotto R, Ashenden MJ, Stray-Gundersen J, Sharpe K, Hopkins W, Emslie KR, Howe C, Trout GJ, Kazlauskas R, Hahn AG.

Haematologica. 2003 Mar;88(3):333-44.

36.

Development of reference ranges in elite athletes for markers of altered erythropoiesis.

Sharpe K, Hopkins W, Emslie KR, Howe C, Trout GJ, Kazlauskas R, Ashenden MJ, Gore CJ, Parisotto R, Hahn AG.

Haematologica. 2002 Dec;87(12):1248-57.

37.

Detection of homologous blood transfusion by flow cytometry: a deterrent against blood doping.

Nelson M, Ashenden M, Langshaw M, Popp H.

Haematologica. 2002 Aug;87(8):881-2. No abstract available.

38.

Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise.

Russell G, Gore CJ, Ashenden MJ, Parisotto R, Hahn AG.

Eur J Appl Physiol. 2002 Mar;86(5):442-9. Epub 2002 Jan 11. Erratum in: Eur J Appl Physiol 2002 Apr;86(6):548.

PMID:
11882931
39.

A strategy to deter blood doping in sport.

Ashenden MJ.

Haematologica. 2002 Mar;87(3):225-32. No abstract available.

40.

Live high:train low increases muscle buffer capacity and submaximal cycling efficiency.

Gore CJ, Hahn AG, Aughey RJ, Martin DT, Ashenden MJ, Clark SA, Garnham AP, Roberts AD, Slater GJ, McKenna MJ.

Acta Physiol Scand. 2001 Nov;173(3):275-86.

PMID:
11736690
41.

A comparison of the physiological response to simulated altitude exposure and r-HuEpo administration.

Ashenden MJ, Hahn AG, Martin DT, Logan P, Parisotto R, Gore CJ.

J Sports Sci. 2001 Nov;19(11):831-7.

PMID:
11695504
42.

An evaluation of the concept of living at moderate altitude and training at sea level.

Hahn AG, Gore CJ, Martin DT, Ashenden MJ, Roberts AD, Logan PA.

Comp Biochem Physiol A Mol Integr Physiol. 2001 Apr;128(4):777-89.

PMID:
11282321
43.

Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis.

Parisotto R, Wu M, Ashenden MJ, Emslie KR, Gore CJ, Howe C, Kazlauskas R, Sharpe K, Trout GJ, Xie M.

Haematologica. 2001 Feb;86(2):128-37.

44.

Reticulocyte parameters as potential discriminators of recombinant human erythropoietin abuse in elite athletes.

Parisotto R, Gore CJ, Hahn AG, Ashenden MJ, Olds TS, Martin DT, Pyne DB, Gawthorn K, Brugnara C.

Int J Sports Med. 2000 Oct;21(7):471-9.

PMID:
11071048
45.

A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes.

Parisotto R, Gore CJ, Emslie KR, Ashenden MJ, Brugnara C, Howe C, Martin DT, Trout GJ, Hahn AG.

Haematologica. 2000 Jun;85(6):564-72.

46.

Simulated moderate altitude elevates serum erythropoietin but does not increase reticulocyte production in well-trained runners.

Ashenden MJ, Gore CJ, Dobson GP, Boston TT, Parisotto R, Emslie KR, Trout GJ, Hahn AG.

Eur J Appl Physiol. 2000 Mar;81(5):428-35.

PMID:
10751105
47.

"Live high, train low" does not change the total haemoglobin mass of male endurance athletes sleeping at a simulated altitude of 3000 m for 23 nights.

Ashenden MJ, Gore CJ, Dobson GP, Hahn AG.

Eur J Appl Physiol Occup Physiol. 1999 Oct;80(5):479-84.

PMID:
10502083
48.

Effects of a 12-day "live high, train low" camp on reticulocyte production and haemoglobin mass in elite female road cyclists.

Ashenden MJ, Gore CJ, Martin DT, Dobson GP, Hahn AG.

Eur J Appl Physiol Occup Physiol. 1999 Oct;80(5):472-8.

PMID:
10502082
49.

Can reticulocyte parameters be of use in detecting iron deficient erythropoiesis in female athletes?

Ashenden MJ, Pyne DB, Parisotto R, Dobson GP, Hahn AG.

J Sports Med Phys Fitness. 1999 Jun;39(2):140-6.

PMID:
10399423
50.

Skin-prick blood samples are reliable for estimating Hb mass with the CO-dilution technique.

Ashenden MJ, Gore CJ, Burge CM, Clough ML, Bourdon PC, Dobson GP, Hahn AG.

Eur J Appl Physiol Occup Physiol. 1999 May;79(6):535-7.

PMID:
10344464

Supplemental Content

Loading ...
Support Center